Emd Serono Research & Development Institute, Inc.

This early-phase study tests a new drug called M9466, a PARP1 inhibitor, alone or combined with other drugs in 60 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and how the body processes the drug. Researchers …

This study follows 205 people with solid tumors who are already taking the cancer drug avelumab. Researchers want to see how safe the drug is over the long term and how long patients live or stay cancer-free. Participants continue their current treatment or are monitored after fi…

This Phase 2 trial tests two experimental drug combinations in 63 women with a specific type of ovarian cancer (BRCA-mutant or HRD-positive) that has worsened after prior PARP inhibitor treatment. Participants receive either tuvusertib plus niraparib or tuvusertib plus larteserti…

This early-stage trial is testing a new drug called tuvusertib, given together with either lartesertib or avelumab, in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see how the body pr…

This study tests an experimental drug called M9140 in people with advanced solid tumors (gastric, lung, or pancreatic cancer) that have a specific protein (CEACAM5). The drug is designed to deliver a toxin directly to cancer cells. About 250 adults will receive the drug alone or …

This study tests a new drug, Tuvusertib, combined with an immunotherapy called Cemiplimab in people with a specific type of advanced lung cancer (non-squamous non-small cell) that has worsened after prior treatments. The trial aims to see if the combination can shrink tumors and …

This early-phase trial tests a new drug called tuvusertib, given alone or with another drug (niraparib), in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to check safety, find the right dose, and see early signs of tumor…

This early-phase trial is testing two drugs, avelumab and lenvatinib, together in children with brain tumors that have not responded to prior treatment. The study has two parts: first, finding a safe dose, and second, seeing if the combination can slow tumor growth. Only 17 child…

This phase 2 trial tests whether adding avelumab (an immunotherapy) to another anti-cancer drug (sacituzumab govitecan) can help prevent advanced bladder cancer from growing after initial chemotherapy. About 256 participants with locally advanced or metastatic urothelial carcinom…

This trial tested the drug tepotinib in 337 people with advanced non-small cell lung cancer that has specific MET gene changes (METex14 skipping or MET amplification). Participants took a 500 mg pill once daily. The main goal was to see if the drug could shrink tumors. The study …

This phase 2 trial tested a combination of two targeted drugs, tepotinib and osimertinib, in 140 people with advanced non-small cell lung cancer that has a specific genetic change (MET amplification) and had stopped responding to the standard drug osimertinib. The goal was to see…